参考文献/References:
[1] Virani SS,A lonso A,B enjamin EJ,et al. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association[J]. Circulation,2020,141(9):e139-e596.
[2] Turakhia MP,Blankestijn PJ,Carrero JJ,et al. Chronic kidney disease and arrhythmias:conclusions from a Kidney Disease:Improving Global Outcomes(KDIGO) Controversies Conference[J]. Eur Heart J,2018,39(24):2314-2325.
[3] Shih CJ,O u SM,C hao PW,et al. Risks of death and stroke in patients undergoing hemodialysis with new-onset atrial fibrillation:a competing-risk analysis of a nationwide cohort[J]. Circulation,2016,133(3):265- 272.
[4] Chen TH,C hu YC,O u SM,et al. Associations of atrial fibrillation with renal function decline in patients with chronic kidney disease[J]. Heart,202 2,108(6):438-444.
[5] Adderley NJ,Ryan R,Nirantharakumar K,et al. Prevalence and treatment of atrial fibrillation in UK general practice from 2000 to 2016[J]. Heart, 2019,105(1):27-33.
[6] Saran R,R obinson B,A bbott KC,et al. US renal data system 2018 annual data report:epidemiology of kidney disease in the United States[J]. Am J Kidney Dis,2019,73(3 suppl 1):A7-A8.
[7] January CT,Wann LS,Calkins H,et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons[J]. Circulation,2019,140(2):e125-e151.
[8] Hindricks G,P otpara T,D agres N,et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS):the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology(ESC) Developed with the special contribution of the European Heart Rhythm Association(EHRA) of the ESC[J]. Eur Heart J,2021,42(5):373-498.
[9] Masson P,W ebster AC,H ong M,et al. Chronic kidney disease and the risk of stroke:a systematic review and meta-analysis[J]. Nephrol Dial Transplant,2015,30(7):1162- 1169.
[10] Molnar AO,B ota SE,G arg AX,et al. The risk of major hemorrhage with CKD[J]. J Am Soc Nephrol,2016,27(9):2825- 2832.
[11] Magnocavallo M,Bellasi A,Mariani MV,et al. Thromboembolic and bleeding risk in atrial fibrillation patients with chronic kidney disease:role of anticoagulation therapy[J]. J Clin Med,2020,10(1):38.
[12] McAlister FA,Wiebe N,J un M,et al. Are existing risk scores for nonvalvular atrial fibrillation useful for prediction or risk adjustment in patients with chronic kidney disease?[J]. Can J Cardiol,2017,33(2):243- 252.
[13] Carrero JJ,Trevisan M,Sood MM,et al. Incident atrial fibrillation and the risk of stroke in adults with chronic kidney disease:The Stockholm CREAtinine Measurements (SCREAM) project[J]. Clin J Am Soc Nephrol,2018,13(9):1314- 1320.
[14] Bhatia HS,Hsu JC,K im RJ. Atrial fibrillation and chronic kidney disease: a review of options for therapeutic anticoagulation to reduce thromboembolism risk[J]. Clin Cardiol,2018,41(10):1395- 1402.
[15] Tapoi L,Ureche C,Sascau R,et al. Atrial fibrillation and chronic kidney disease conundrum:an update[J]. J Nephrol,2019,32(6):909- 917.
[16] Ravera M,Bussalino E,Fusaro M,et al. Systematic DOACs oral anticoagulation in patients with atrial fibrillation and chronic kidney disease:the nephrologist’s perspective[J]. J Nephrol,2020,33(3):483-495.
[17] Ha JT,N euen BL,C heng LP,et al. Benefits and harms of oral anticoagulant therapy in chronic kidney disease:a systematic review and meta-analysis[J]. Ann Intern Med,2019,171(3):181- 189.
[18] Stanifer JW,Pokorney SD,Chertow GM,et al. Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease[J]. Circulation,2020,141(17):1384-1392.
[19] Coleman CI,Kreutz R,Sood NA,et al. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and severe kidney disease or undergoing hemodialysis[J]. Am J Med,2019,132(9):1078- 1083.
[20] de V riese AS,Heine G. Anticoagulation management in hemodialysis patients with atrial fibrillation:evidence and opinion[J]. Nephrol Dial Transplant,2021 Feb 27;gfab060. DOI:10.1093/ndt/gfab060. Online ahead of print.
[21] Guo Y,Kotalczyk A,Imberti JF,et al. Poor adherence to guideline-directed anticoagulation in elderly Chinese patients with atrial fibrillation. A report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation(ChiOTEAF) registry[J]. Eur Heart J Qual Care Clin Outcomes,2021 Aug 9;qcab054. DOI:10.1093/ehjqcco/qcab054. Online ahead of print.
[22] Ding WY,L ip GYH,Shantsila A. Relationship between chronic kidney disease,time-in-therapeutic range,and adverse outcomes in atrial fibrillation:a post hoc analysis from the AMADEUS trial[J]. Cerebrovasc Dis,202 2,51(1):29-35.
[23] Brodsky S,Eikelboom J,Hebert LA. Anticoagulant-related nephropathy[J]. J Am Soc Nephrol,2018,29(12):2787-2793.
[24] Osmancik P,H erman D,N euzil P,et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation[J]. J Am Coll Cardiol,2020,75(25):3122- 3135.
[25] Turagam MK,Osmancik P,Neuzil P,et al. Left atrial appendage closure versus oral?anticoagulants in atrial fibrillation:a meta-analysis of randomized trials[J]. J Am Coll Cardiol,2020,76(23):2795-2797.
[26] Reddy VY,Akehurst RL,Amorosi SL,et al. Cost- effectiveness of left atrial appendage closure with the WATCHMAN device compared with warfarin or non-vitamin K antagonist oral anticoagulants for secondary prevention in nonvalvular atrial fibrillation[J]. Stroke,2018,49(6):1464-1470.
[27] Kefer J,T zikas A,F reixa X,et al. Impact of chronic kidney disease on left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation[J]. Int J Cardiol,2016,207:335- 340.
[28] Xue X,J iang L,Duenninger E,et al. Impact of chronic kidney disease on Watchman implantation:experience with 300 consecutive left atrial appendage closures at a single center[J]. Heart Vessels,2018,33(9):1068- 1075.
[29] Fastner C,Brachmann J,Lewalter T,et al. Left atrial appendage closure in patients with chronic kidney disease:results from the German multicentre LAARGE registry[J]. Clin Res Cardiol,2021,110(1):12-20.
[30] Ahuja KR,A riss RW,N azir S,et al. The association of chronic kidney disease with outcomes following percutaneous left atrial appendage?closure[J]. JACC Cardiovasc Interv,2021,14(16):1830- 1839.
[31] Faroux L,C ruz-González I,A rzamendi D,et al. Effect of glomerular filtration rates on outcomes following percutaneous left atrial appendage closure[J]. Am J Cardiol,2021,145:77-84.
[32] Genovesi S,P orcu L,S laviero G,et al. Outcomes on safety and efficacy of left atrial appendage occlusion in end stage renal disease patients undergoing dialysis[J]. J Nephrol,2021,34(1):63-73.
[33] 李亚会,黄从新. 左心耳封堵术常见并发症及其防治[J]. 心血管病学进展,2021,42(5):408-410,416.
[34] 谭素敏,杨磊,边原,等. 心房颤动患者左心耳封堵术后抗栓策略[J]. 中国新药与临床杂志,2022,41(1):12-16.
[35] 金灿,罗俊,武英彪,等. 心房颤动伴慢性肾脏病患者经皮左心耳封堵术后抗栓治疗方案研究[J]. 介入放射学杂志,2020,29(12):1187-1190.
[36] Merella P,Lorenzoni G,Delitala AP,et al. Left atrial appendage occlusion in high bleeding risk patients[J]. J Interv Cardiol,2019,2019:6704031.
[37] Ledwoch J,Sievert K,Boersma LVA,et al. Initial and long-term antithrombotic therapy after left atrial appendage closure with the WATCHMAN[J]. Europace,2020,22(7):1036-1043.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(9):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(9):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(9):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(9):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(9):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(9):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(9):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(9):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(9):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(9):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]